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Abstract Since the 1990’s cabergoline has been the treat-
ment of choice in prolactinoma, as it permits rapid and
effective hormonal and tumor control in most cases. Evi-
dence of cardiac valvulopathy was demonstrated in Par-
kinson’s disease patients treated with dopamine agonists.
Retrospective studies in prolactinoma patients treated with
cabergoline at lower doses did not show such an effect.
However, few prospective data with long-term follow-up
are available. The aim of this study was to assess the safety
of cabergoline regarding cardiac valvular status during
prospective follow-up in patients treated for prolactinoma or
idiopathic hyperprolactinemia. We report here a series of
100 patients (71F; median age at diagnosis: 41.5 years)
treated with cabergoline for endocrine diseases (prolacti-
noma n= 89, idiopathic hyperprolactinemia n= 11). All
patients underwent complete transthoracic echocardio-
graphic studies at baseline and during long-term prospective
surveillance using the same equipment and performed by
the same technicians. The median interval between baseline
and last follow-up echocardiographic studies while on
cabergoline was 62.5 months (interquartile range:
34.75–77.0). The median total duration of cabergoline
treatment was 124.5 months (interquartile range:
80.75–188.75) and the median cumulative total dose of
cabergoline was 277.8 mg (interquartile range :
121.4–437.8 mg) at last follow-up. We found no clinically
relevant alterations in cardiac valve function or valvular
calciﬁcations with cabergoline treatment. Our data suggest
that ﬁndings from retrospective analyses are correct and that
cabergoline is a safe chronic treatment at the doses used
typically in endocrinology.
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Introduction
An increased risk of cardiac valve disease has been seen in
patients treated for Parkinson’s disease using high doses of
ergot-derived dopamine agonists like cabergoline and per-
golide [1]. The mechanisms underlying this effect have
been studied widely [2–4]. In Parkinson’s disease a corre-
lation between the cumulative dose of dopamine agonists
and the severity of cardiac valve regurgitation has been
reported [5–8].
Since the 1990’s, cabergoline has become the ﬁrst line
treatment for hyperprolactinemia [9–12]. Its widespread use
raised questions about its safety in the endocrine setting, as
it is used chronically, although the doses used in endocri-
nology are lower than those used in Parkinson's disease.
Our ﬁrst cross-sectional study in 2008 did not ﬁnd any
relevant valvulopathy in patients treated with dopamine
agonists at doses typically used in the endocrine setting
[13]. While these results were reassuring, relatively little
information on long term use of cabergoline and cardiac
valve status are available. We report here a prospective
follow-up study of 100 patients treated with cabergoline for
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hyperprolactinemia, in which there was at least one year of
follow-up between echocardiographic studies.
Methods
Patient population
The study population consisted of 100 subjects who
received cabergoline treatment for prolactin secreting
microadenomas (n= 46), macroadenomas (n= 43) or idio-
pathic hyperprolactinemia (n= 11) and underwent echo-
cardiographic surveillance as part of the standard hospital
protocol. Three patients included in the study had not pre-
viously received cabergoline before the ﬁrst cardiac echo-
graphy whereas the other 97 patients had already been
treated. The cumulative dose of cabergoline was calculated
for each patient. Data on other risk factors for cardiac valve
disease were collected with particular attention paid to
hypertension, diabetes mellitus, obesity, hypercholester-
olemia and smoking.
Each patient underwent at least two cardiac ultrasound
evaluations, with a minimum of 12 months between
assessments. The retrospective period was deﬁned as the
period up to the ﬁrst ultrasound evaluation (baseline ﬁnd-
ings) while the prospective period extended from the ﬁrst to
the last echocardiography (follow-up ﬁndings). All the
patients and controls consented to the performance
of echocardiographic surveillance and the study was
approved by the Ethics Committee of the Center Hospitalier
Universitaire de Liège
Controls
As previous studies have not addressed baseline valvular
status as compared to healthy (non-cardiac disease) controls,
we recruited a cohort of 60 anonymized healthy individuals
that were matched for age and sex with the patient popula-
tion. In the control group, the rates of valvular regurgitation
for the four cardiac valves were as follows: tricuspid
valve–grade 0 (n= 30), grade 1 (n= 25), grade 2 (n= 5);
mitral valve–grade 0 (n= 33), grade 1 (n= 27), grade 2
(n= 0); aortic valve–grade 0 (n= 53), grade 1 (n= 7), grade
2 (n= 0); pulmonary valve–grade 0 (n= 34), grade 1
(n= 24), grade 2 (n= 2). None of the control subjects had
evidence of calciﬁcation or grade 3 valvular insufﬁciencies
at baseline. The mitral valve tenting area was normal in all
control subjects (median: 1.20 cm2 (IQR: 1.10–1.40 cm2)).
The echocardiographic results of this control group were
compared with the patient cohort in terms of valve char-
acteristics at baseline.
Echocardiographic measurements
All patients and controls underwent a complete transthor-
acic echocardiographic examination using the same equip-
ment (Vivid 7 GE, Vingmed Ultrasound, Horten, Norway).
All echocardiograms were performed by two experienced
echocardiographers, with special attention towards valvular
status and these cardiograms were interpreted by a third
echocardiographer. Echocardiographic and Doppler data
were obtained in digital format and stored on optical disks
for off-line analysis. Valvular regurgitation was diagnosed
using color-coded doppler and by imaging multiple views.
Quantiﬁcation of regurgitant valve disease was made
according to the guidelines of the American Society of
Echocardiography [14]. Valve regurgitation was graded on
a 0–3 scale as absent, mild (not signiﬁcant), moderate, or
severe. Abnormal leaﬂet or cusp thickening was judged to
be present when the thickness (localized or widespread)
exceeded 5 mm [6, 8]. Mitral and tricuspid valves were
regarded as restrictive if leaﬂet stiffening and retraction
towards the apex was identiﬁed. Mitral valvular tenting area
—a marker of the apical displacement of mitral leaﬂets—
was obtained from the parasternal long axis view at mid-
systole and measured the area enclosed between the annular
plane and the mitral leaﬂets [15, 16]. The aortic valve was
judged as being restrictive if the valve opened with visibly
evident doming of the leaﬂets. Systolic pulmonary artery
pressure was estimated from the systolic trans-tricuspid
pressure gradient (in mmHg) using the simpliﬁed Bernoulli
equation. Classiﬁcation of valvular status was made
according to the American Society of Echocardiography
and was summarized as follows [14]:
grade 0: no dysfunction
grade 1: mild regurgitation (grade 1 regurgitation is
considered not clinically signiﬁcant)
grade 2: moderate regurgitation
grade 3: severe regurgitation
Statistical analysis
Data were imported into the R statistical package. Con-
tinuous variables were tested for normality. Since none of
the continuous variables showed a normal distribution, they
were described in the article as medians and inter-quartiles
ranges (IQR). The total range was also reported where
relevant. The control and cabergoline treated subjects were
divided in subgroups based on sex and current age (<30,
30–40, 41–50, 51–60, >60 years).
For mitral valve tenting area data, statistical comparison
of control cases versus cabergoline-treated patients at
baseline was made using the Kruskal-Wallis test on each
subgroup. Comparison of tenting data in the cohort at
baseline and last assessment were performed using the
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paired version of the Kruskall-Wallis test. For valvular
insufﬁciencies, the score (0–4) was tested by binning the
number of patients for each score value, then testing the
corresponding contingency table with a chi-square test. This
test was performed ﬁrst for the age and sex-related sub-
groups of controls versus patients and then for the data of
patients at baseline versus their last evaluation. Statistical
signiﬁcance was assessed based on a p-value< 0.05.
Results
The patient cohort consisted of 70 women and 30 men. The
median age at the diagnosis was 41.5 years (IQR: 28–51
years). The median total duration of cabergoline treatment
was 124.5 months (IQR: 80.7–188.7 months) and the
median cumulative dose of cabergoline was 277.8 mg (IQR:
121.4–437.8 mg) at last follow-up. Cardiovascular risk
factors at baseline included: dyslipidemia (n= 25), obesity
(n= 28), hypertension (n= 22), diabetes mellitus
(n= 10) and smoking (n= 19).
Retrospective period: baseline ﬁndings at ﬁrst
echocardiographic evaluation
The median duration of treatment before the baseline
echocardiographic examination (the retrospective period)
was 62.5 months in the patient population (IQR:
24.75–132.0 months; Range: 0–276 months). The median
dose of cabergoline during that period was 139.38 mg (IQR:
31.88–323.75 mg). Moderate mitral valve regurgitation was
found in four female cabergoline-treated patients at base-
line. None had dilated cardiomyopathy or renal failure. In
another four female patients, mild tricuspid insufﬁciency
was present at baseline but none had pulmonary hyperten-
sion (Table 1). No patient had aortic or pulmonary valvu-
lopathy at baseline. The median mitral valve tenting area
was normal in the patient cohort at baseline (1.26 cm2 (IQR:
1.10–1.40 cm2)). As compared to normal controls, there was
no signiﬁcant difference in terms of mitral valve tenting in
patient cohort at baseline (p=NS). At baseline, there were
no signiﬁcant differences between the healthy controls as a
whole and the patient population in terms of the frequencies
of valvular regurgitation; similarly no signiﬁcant, clinically
relevant differences were seen between the healthy controls
and the patients when analyzed separately by age and sex
(p=NS).
Prospective period: follow-up ﬁndings at last
echocardiographic evaluation
The median duration of the prospective follow-up period
from baseline to last echocardiographic evaluation was
62.5 months (IQR: 34.75–77.0 months; range:
12–92 months). The median dose of cabergoline in the
prospective period alone was 85.75 mg (IQR: 35.5–171.5
mg). As noted above, the median cumulative (retrospective
plus prospective period) cabergoline dose was 277.8 mg
(IQR: 121.4–437.8 mg).
Evolution of valvular status during follow-up of our
population is shown in Fig. 1. During the prospective per-
iod, one patient developed moderate tricuspid regurgitation.
This patient was a 43-year-old female with a macroadenoma
at diagnosis. Her PRL levels were 1339 μU/mL at diagnosis
and she had surgery and cabergoline treatment with a total
cumulative dose of 541.7 mg over the course of 239 months
of treatment. Three patients developed a new ﬁnding of
mild (clinically non signiﬁcant) aortic insufﬁciency. Three
patients developed mild pulmonary valvular insufﬁciency
(not clinically signiﬁcant), while two other cases of pre-
existing mild insufﬁciency normalized during prospective
follow-up.
No signiﬁcant variations in mitral function were found
across the course of the prospective study. Of the four
women that had moderate (grade 2) mitral regurgitation,
three remained stable while one decreased in severity during
the prospective follow-up. In these patients, the follow up
period ranged from 77 to 261 months and the cumulative
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cabergoline dose range ranged from 256.25 to 292.0 mg
(Table 1). Table 2 shows the evolution of each cardiac valve
between baseline and last follow-up examinations. The
median mitral valve tenting area at the last follow up was
1.27 cm2 (IQR: 1.03–1.47 cm2), which was not signiﬁcantly
different from baseline (p= 1.0).
Discussion
In 1997, Connolly et al. reported a series of 24 cases of
unusual valvulopathy in patients treated with fenﬂuramine
and phentermine, two anorectic drugs frequently used in the
USA at the time [17]. Both were already known to be
responsible, when used alone, for pulmonary hypertension.
Regurgitation was found in all patients and
echocardiography showed a particular valvular morphol-
ogy, resulting in thickening of the anterior mitral leaﬂet, but
both the right-sided and left-sided heart valves were
involved. As this kind of valvulopathy was already descri-
bed in patients suffering for carcinoid disease [18, 19] and
in patients taking serotonin-like drugs [20], a common
pathway for these valvulopathies was suggested. In 2000,
Rothman et al. reported that activation of 5-
hydroxytryptamine subtype 2 receptor (5-HT2B), which is
highly expressed in human cardiac valves, is required to
develop this cardiac valvular disease [2]. In consequence,
mitogenesis and proliferation of ﬁbroblasts progressively
lead to an overgrowth valvulopathy [3, 4]. Since then,
particular attention was paid to other ergot dopamine ago-
nists such as bromocriptine, pergolide and cabergoline,
usually used in the treatment of Parkinson’s disease [1].
Fig. 1 Frequencies of valvular regurgitation on echocardiography in patients treated with cabergoline at baseline and at last follow-up
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Indeed, in Parkinson's disease patients taking either caber-
goline or pergolide, an increased risk of newly diagnosed
degenerative heart valve disease is now well established.
During the 1990’s, cabergoline became the ﬁrst-line
treatment for prolactinomas and hyperprolactinemia.
Cabergoline is used at much lower doses in the endocrine
setting than those used for Parkinson’s disease. Cabergoline
is usually well tolerated and highly effective in controlling
prolactin hypersecetion and can also reduce tumor size. At
doses within the indicated range of about 2 mg per week,
resistance to cabergoline treatment is rare. A recent multi-
center study in 92 resistant prolactinomas reported that they
comprised only about 3.4 % of prolactinomas overall,
although this rate rose to 13 % in those with a genetic
component to their tumorigenesis [21], such as AIP muta-
tion [22, 23]. Cabergoline has a long half-life and its potent
D2 receptor afﬁnity leads to a rapid and effective control of
many prolactinomas. As this pathology affects people at a
young age and as it requires chronic therapy, cumulative
doses of cabergoline can be quite high. Our initial retro-
spective study in prolactinoma patients did not ﬁnd any
relationship between cabergoline dose and the presence or
severity of mitral valve regurgitation. In that study, mitral
valve tenting area was signiﬁcantly greater in the cabergo-
line group when compared with control subjects and mitral
valve leaﬂet thickening was observed in 5.9 % of
cabergoline-treated subjects [13]. However, no relationship
with the cumulative cabergoline dose was found and none
of the patients had aortic or tricuspid valvular restriction
[13]. In consequence, our subjects treated with long-term
cabergoline therapy did not have a statistically signiﬁcantly
increased risk of clinically relevant cardiac valve disease.
These results are concordant with most other studies [24–
30]. Only one study found signiﬁcant tricuspid valve
regurgitation in patients receiving high cumulative doses of
cabergoline [31]. Signiﬁcant aortic valvular calciﬁcation
was also reported in another study [32]. However, pro-
spective data with long-term follow-up are relatively sparse.
Maione et al. reported cardiac evaluation of acromegalic
patients receiving cabergoline. In that study, a group of 26
patients treated with cabergoline was compared to 26
acromegalic controls not treated with cabergoline and with a
similar duration of follow-up [33]. During the follow-up
period of at least four years, the incidence of valve regur-
gitation and remodeling was the same in both groups.
Another study reported a higher degree of aortic valvular
calciﬁcations in a series of 74 patients treated with caber-
goline that were followed for two years [34]. That study was
a prospective follow-up evaluation of the previous study by
Kars et al., in which a high baseline frequency of aortic
valve calciﬁcation was noted. In the prospective assessment,
no increase of the rate of valve dysfunction or calciﬁcation
was reported.
In the current cohort of 100 patients treated with caber-
goline for prolactinoma and hyperprolactinemia, the risk of
developing moderate or signiﬁcant cardiac valve lesions
was not increased. Follow-up was at least one year, but the
median follow-up was much longer, at nearly 10 years and
the cumulative median dose of cabergoline was >277 mg.
None of the handful of moderate mitral or tricuspid regur-
gitation cases noted at baseline worsened signiﬁcantly
during follow-up. These results are in keeping with other
data from prospective analyses [33–35]; however, in con-
trast to Delgado et al., we did not identify any cases of
signiﬁcant calciﬁcation despite similar mean ages at diag-
nosis in the two studies. Many factors can inﬂuence valv-
ular calciﬁcations (dyslipidemia, age, hypertension, renal
failure, hyperphosphatemia) and discrepancies between
studies might be explained by differences in the populations
studied. We had a healthy control group for our baseline
comparisons, an important point that is missing from many
studies of this type. Information on normative data on the
healthy general population would help to set in context
whether the very minor variations in clinically non-relevant
valve characteristics is related to cabergoline treatment or
whether it merely reﬂects the expected changes that nor-
mally occur in the general population over time.
In our series we found tricuspid insufﬁciency in four
cases at baseline. Mild tricuspid regurgitation can be found
in approximately 70 % of the general population [14].
Table 2 Comparison of evolution of valve status between baseline
and last echocardiographic evaluations in 100 patients
Tricuspid insufﬁciency Baseline evaluation Final evaluation
p= 0.3655
Grade 0 (n) 59 49
Grade 1 (n) 37 46
Grade 2 (n) 4 5
Mitral insufﬁciency
p= 0.9253
Grade 0 (n) 56 56
Grade 1 (n) 40 41
Grade 2 (n) 4 3
Aortic insufﬁciency
p= 0.8277
Grade 0 (n) 89 87
Grade 1 (n) 11 13
Grade 2 (n) 0 0
Pulmonary insufﬁciency
p= 1.0
Grade 0 (n) 86 85
Grade 1 (n) 14 15
Grade 2 (n) 0 0
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Moderate-to-severe regurgitation is rarer and is frequently
functional [36], is accompanied by pulmonary hypertension
and is associated with a poor survival rate [37]. In our
series, none of our patients had risk factors for developing
tricuspid regurgitation (apart, theoretically, from cabergo-
line). Crucially, none had worsening of their tricuspid
valvular status during follow-up.
Recently, De Vecchis reported a meta-analysis about the
use of cabergoline and the risk of developing cardiac valve
disease [38]. Regarding cabergoline use in the endocrine
setting, they did ﬁnd a trend to develop mild to moderate
valve regurgitation. In their analysis, they included seven
studies [13, 24, 26, 31, 32, 39, 40] comparing data of 444
treated cases versus 954 controls. They conclude that
although globally safe, a periodic ultrasound assessment
should not be avoided even if cabergoline dose is low.
However, as prevalence of valvular abnormality is low,
annual evaluation seems not to be necessary except in some
selected cases [41].
The involvement of cabergoline in cardiac valvulopathy
is now well established in Parkinson’s disease. Our pro-
spective study conﬁrms that the use of cabergoline did not
increase the risk of valvular disease in our series of patients
with prolactinoma and hyperprolactinemia. Taken together
with other retrospective, prospective and meta-analytic data,
we believe cabergoline therapy at doses used in endocrine
practice is safe for the vast majority of patients. Periodic
assessments of cardiac valve function may be necessary in
patients with other risk factors for valvulopathy and in those
with established valve dysfunction at baseline.
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